Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Cosmetic – antiperspirant – dentifrice
Reexamination Certificate
2005-05-10
2005-05-10
Page, Thurman K. (Department: 1616)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Cosmetic, antiperspirant, dentifrice
C424S078050, C514S862000, C514S871000
Reexamination Certificate
active
06890544
ABSTRACT:
Composition for topical administration comprising (a) a corticosteroid, and (b) a drying agent.
REFERENCES:
patent: 4569935 (1986-02-01), Rosenberg et al.
patent: 5110809 (1992-05-01), Wang et al.
patent: 5219877 (1993-06-01), Shah et al.
patent: 5478814 (1995-12-01), Packman
patent: 5883085 (1999-03-01), Blank et al.
patent: 5972920 (1999-10-01), Seidel
patent: 6391282 (2002-05-01), Dugger, III
patent: 1095615 (1994-11-01), None
patent: 1111984 (1995-11-01), None
patent: 173478 (1986-03-01), None
patent: WO 9214472 (1992-09-01), None
patent: WO 9727862 (1997-08-01), None
Martin H. Wortzel A Double-Blind Study Comparing the Superiority of a combination Antifungal (Clotrimazole)/Steroidal (Betamethasone Dipropionate) Product, CUTIS, vol. 30, (Aug. 1982) pp.258-261.
G. V. Jaffe et al. “An Open Trial of Clotrimazole Plus Hydrocortisone Cream in the Treatment of Napkin Dermatitis in General Practice” Pharmatherapeutica, vol. 4, No. 5 (1985) pp. 314-318.
Richard E. Stoughton “Are Generic Formulations Equivalent to Trade Name Topical Glucocorticoids?” Archives of Dermatology, vol. 123 (Oct. 1987) pp. 1312-1314.
Richard E. Soughton “Bioassay System for Formulations of Topically Applied Glucocorticosteroids” Archives of Dermatology, vol. 106 (Dec. 1972) pp. 825-827.
David B. Jackson et al. “Bioequivalence (bioavailability) of General Topical Corticosteroids” Journal of the American Academy of Dermatology, vol. 20, No. 5, Pt. 1 (May 1989) pp. 791-796.
Cynthia A. Guzzo et al. “Chapter 64, Dermatological Pharmacology” Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., McGraw-Hill (1996) pp. 1593-1598.
G. S. Shankland et al. “Comparative in-vitro Activity of Clortimazole and a Clotrimazole/hydrocortisone Combination in the Treatment of Experimental Dermatophytosis in Guinea Pigs” Journal of Antimicrobial Chemotherapy, vol. 25 (1990) pp. 825-830.
Roger C. Cornell et al. “Correlation of the Vasoconstriction Assay and Clinical Activity in Psoriasis” Arch Dermatol, vol. 121 (Jan. 1985) pp. 63-67.
Thomas B. Fitzpatrick et al. Dermatology In General Medicine, vol. II, 4th Ed., McGraw-Hill, Inc., (1993) pp. 2444-2447 and 2847.
E.G.V. Evans et al. “Does Naftifine Have Anti-Inflammatory Properties? A Double-blind Comparative Study With 1% Clotrimazole/1% Hydrocortisone in Clinically Diagnosed Fungal Infection of the Skin” British Journal of Dermatology, vol. 29 (1993) pp. 437-442.
Steven K. Hebel et al. “Drug Facts and Comparisons” Facts and Comparisons, St. Louis, A Wolters Kluwer Company (Jan. 2000) pp. ii, 1658, 1659,1684.
Sandra Levy “Latest Switch—Lamisil—Offers to Get it Done Faster” Drug Topics, Apr. 19, 1999, pp. 72.
A. W. McKenzie et al. “Method for Comparing Percutaneous Absorption of Steroids” Archive of Dermatology, vol. 86, (1962) pp. 608-610.
Virgil A. Place et al. “Precise Evaluation of Topically Applied Corticosteroid Potency” Archives of Dermatology, vol. 101 (May 1970) pp. 531-537.
H. Irving Katz et al. “SCH 370 (Clotirmazole-Betamethasone Dipropionate) Cream in Patients with Tinea Cruris or Tinea Corporis” vol. 34 (Aug. 1984) pp. 183-188.
Paul Walsh et al. “Schering, Lotrisone” Physicians' Desk Reference PFR 55ed 2001, pp. 2912-2914.
A. R. W. Bowring et al. “The Treatment of Napkin Dermatitis: a Double-Blind Comparison of Two Steroid-Antibiotic Combinations” Pharmatherapeutica, vol. 3, No. 9 (1984) pp. 613-617.
Richard E. Soughton “Vasoconstrictor Activity and Percutaneous Absorption of Glucocorticosteroids”Archives of Dermatology, vol. 99 (Jun. 1969) pp. 753-756.
Facts and Comparisons, on Aveeno® anti-itch, by Rydelle, revised May 1992, p. 564a.
Physician's Desk Reference, on Caldry®, by Pfizer, obtained from PDR on-line, (1995).
“USP 24, NF 19” U.S. Pharmacopeia & National Formulary, The United States Pharmacopeial Convention, Inc. 12601 Twinbrook Parkway, Rockville, MD (1999) pp. 273-274, 1768-1769.
Haghighatian Mina
Page Thurman K.
Senniger Powers
LandOfFree
Gel composition for the topical treatment of poison ivy and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gel composition for the topical treatment of poison ivy and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gel composition for the topical treatment of poison ivy and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3392141